Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Dabrafenib plus trametinib for stage III mutant melanoma

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 628

Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

Dr Hauschild presents in a press conference at the ESMO 2017 congress in Madrid data from the COMBI-AD trial looking at adjuvant dabrafenib plus trametinib for resected stage III BRAF V600E/K–mutant melanoma. 

Dr Hauschild goes on to discuss the results of the trial, highlighting the 53% improvement in relapse free survival rates. 

Dr Hauschild spoke with ecancer about the results here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence